Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Matthaios D, Balgkouranidou I, Karayiannakis A, Bolanaki H, Xenidis N, Amarantidis K, Chelis L, Romanidis K, Chatzaki A, Lianidou E, Trypsianis G, Kakolyris S.

Oncol Lett. 2016 Jul;12(1):748-756. Epub 2016 Jun 1.

2.

Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.

Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S.

Mutat Res. 2015 Aug;778:46-51. doi: 10.1016/j.mrfmmm.2015.05.002. Epub 2015 Jun 11.

PMID:
26073472
3.

A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.

Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group.

Breast. 2013 Dec;22(6):1171-7. doi: 10.1016/j.breast.2013.08.017. Epub 2013 Oct 1.

PMID:
24091128
4.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17.

5.

Reversible posterior leukoencephalopathy syndrome induced by pazopanib.

Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P, Michailidis P, Christakidis E, Prassopoulos P, Kakolyris S.

BMC Cancer. 2012 Oct 22;12:489. doi: 10.1186/1471-2407-12-489.

6.

Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy.

Riga MG, Chelis L, Kakolyris S, Papadopoulos S, Stathakidou S, Chamalidou E, Xenidis N, Amarantidis K, Dimopoulos P, Danielides V.

Am J Clin Oncol. 2013 Feb;36(1):1-6. doi: 10.1097/COC.0b013e31822e006d.

PMID:
22134515
7.

Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.

Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulos P, Kakolyris S.

Cancer Chemother Pharmacol. 2012 Feb;69(2):477-84. doi: 10.1007/s00280-011-1717-6. Epub 2011 Aug 20.

PMID:
21858532
8.

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, Tentes A, Deftereos S, Karanikas M, Karayiannakis A, Kakolyris S.

Oncology. 2011;80(5-6):359-65. doi: 10.1159/000330199. Epub 2011 Jul 29.

PMID:
21811088
9.

Synchronous carcinoma of the ampulla of vater and colon cancer.

Karayiannakis AJ, Kakolyris S, Kouklakis G, Xenidis N, Bolanaki H, Tsalikidis C, Simopoulos C.

Case Rep Gastroenterol. 2011 May;5(2):301-7. doi: 10.1159/000329344. Epub 2011 May 28.

10.

Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer.

Chelis L, Xenidis N, Amarantidis K, Prassopoulos P, Chamalidou E, Neanidis K, Mikroulis D, Chatzaki E, Karakitsos P, Kakolyris S.

Chemotherapy. 2010;56(5):353-8. doi: 10.1159/000321549. Epub 2010 Oct 7.

PMID:
20926858
11.

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.

Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Jul;68(1):63-8. doi: 10.1007/s00280-010-1427-5. Epub 2010 Sep 10.

PMID:
20830475
12.

Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.

Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, Maltezos E, Kakolyris S.

Med Oncol. 2011 Dec;28 Suppl 1:S165-8. doi: 10.1007/s12032-010-9669-y. Epub 2010 Aug 31.

PMID:
20809183
13.

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC.

Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1239-45. doi: 10.1007/s00280-010-1415-9. Epub 2010 Aug 10.

PMID:
20697712
14.

Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.

Xenidis N, Neanidis K, Amarantidis K, Dimopoulos P, Chamalidou E, Pitsiava D, Tentes A, Chatzaki E, Karakitsos P, Kakolyris S.

Cancer Chemother Pharmacol. 2011 Jan;67(1):69-73. doi: 10.1007/s00280-010-1284-2. Epub 2010 Mar 11.

PMID:
20221602
15.

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.

Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S.

Acta Oncol. 2010;49(2):245-51. doi: 10.3109/02841860903253553.

PMID:
19839918
16.

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S.

Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23.

PMID:
19783319
17.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.

Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2009 Aug 18;101(4):589-97. doi: 10.1038/sj.bjc.6605183. Epub 2009 Jul 21.

18.

Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2009 May 1;27(13):2177-84. doi: 10.1200/JCO.2008.18.0497. Epub 2009 Mar 30.

PMID:
19332733
19.

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Erratum in: Breast Cancer Res Treat. 2009 Oct;117(3):539.

PMID:
19016323
20.

Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.

Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.

Clin Breast Cancer. 2007 Dec;7(11):883-9. doi: 10.3816/CBC.2007.n.054.

PMID:
18269779

Supplemental Content

Loading ...
Support Center